Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Launched by ASSIUT UNIVERSITY · Nov 25, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a substance called Monocyte Chemoattractant Protein-1 (MCP-1) in patients with Psoriatic Arthritis (PsA), a condition that causes joint pain and skin issues. The researchers want to see if MCP-1 levels in the blood are different in people with PsA, especially those who may also have heart problems. They aim to find early signs of heart issues in these patients so that they can be diagnosed and treated sooner.

To participate in this trial, you must be at least 18 years old and have been diagnosed with PsA according to specific criteria. However, people with certain conditions, such as infections, other autoimmune diseases, diabetes, high blood pressure, and kidney or liver diseases, will not be eligible to join. If you qualify, you can expect to provide blood samples for testing and be part of a study that could help improve the understanding and management of PsA and its potential effects on heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria\[15\]for psoriatic arthritis
• Exclusion Criteria:
• • PsA patients with
• • 1. infection.
• • 2. bone marrow disorders.
• • 3. other autoimmune diseases.
• • 4. diabetes.
• • 5. hypertention .
• • 6. hyperlipidemia.
• • 7. liver diseases.
• • 8. renal diseases.